Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

COVID and beyond: labs unite to boost genomic surveillance globally

Published 01/25/2024, 12:42 PM
Updated 01/25/2024, 04:20 PM
© Reuters. FILE PHOTO: A medical worker administers a dose of the "Cominarty" Pfizer-Bivalent coronavirus disease (COVID-19) vaccine to a patient at a vaccination centre in Nice, December 7, 2022. REUTERS/Eric Gaillard/File Photo

By Jennifer Rigby

CAMBRIDGE, England (Reuters) - Two laboratories in Britain and South Africa, which were at the forefront of tracking new coronavirus variants during the pandemic, have teamed up to keep the focus on genomic surveillance globally as the COVID emergency recedes.

The teams said they were worried governments and funders may pull back from such surveillance, despite its potential to better monitor many infectious diseases, from malaria to cholera.

"One of the big benefits that came from the pandemic was this huge global investment in infrastructure," said John Sillitoe, director of the Genomic Surveillance Unit (GSU) at the Wellcome Sanger Institute in Cambridge, one of the two partners.

In genomic surveillance, scientists first get data about the genetic material of a virus or organism in a process called sequencing. Then they analyse the data from several samples to look for similarities and differences between them, for example to track how the virus is changing or spreading.

The process has been around for decades, but came to the forefront as scientists and public health teams tracked the fast-changing coronavirus.

But Sillitoe said he feared assets needed for the process - like sequencing machines bought in the pandemic - were now "sitting idle" in some countries, which would be a missed opportunity.

"We have a lot of blind spots, both on pathogens and on regions," said Tulio de Oliveira, director of the Centre for Epidemic Response and Innovation at Stellenbosch University, the other lab in the partnership. During COVID, his team confirmed the discovery of the Beta and Omicron variants.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

De Oliveira, who will also join the GSU as a deputy director, said the potential for other diseases was huge.

For example, work by the two labs, as well as a global climate-related disease consortium, has doubled the number of sequences available for dengue, chikungunya, and malaria-carrying mosquitoes in just the last year, he said.

The labs will work together to share resources as well as supporting partners in disease surveillance globally with expertise and materials, alongside wider World Health Organization-led efforts, de Oliveira and Sillitoe said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.